Drug Approval | September 22, 2024
Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
The inspections concluded with no Form 483 observations or significant critical findings
_256_384.jpg)
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
The company is committed to address this observation comprehensively within stipulated time
_256_384.jpg)
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
